The content on this site is intended for healthcare professionals only
IMW 2017 highlights
Outcome of third salvage autologous stem cell transplantation in multiple myeloma
Treatment of multiple myeloma patients in the relapsed setting: Expert discussion from IMW 2017
Evaluating efficacy of denosumab compared with zoledronic acid in symptomatic myeloma
Multiple myeloma highlights from IMW 2017
Long term effects of myeloma treatment
Update on CASTOR trial: Daratumumab, bortezomib, and dexamethasone for relapsed or refractory myeloma
Caring for multiple myeloma carers
Impact of recurrent myeloma alterations on drug response
What is the biology behind immunotherapy for MM?
Evolving role of MRD negativity in multiple myeloma
Role of immunotherapy and precision medicines in multiple myeloma and key new guidelines
Carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma
Is precision myeloma medicine more hype than reality?
Asia-Pacific approaches to myeloma trials
Denosumab vs zoledronic acid for bone disease in newly diagnosed multiple myeloma
Bone disease and management of myeloma complications
Monoclonal antibodies in multiple myeloma
Treatment options for newly diagnosed multiple myeloma and management of bone disease: Roundtable at IMW 2017
Promising myeloma agents in phase II trials
Ongoing transplant phase III trials for myeloma
Post autologous transplant therapies in high risk multiple myeloma: StaMINA trial update
Updates from ASPIRE and ENDEAVOR: Multicenter phase III studies of carfilzomib for relapsed/refractory multiple myeloma
Pomalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma
How should we treat smoldering multiple myeloma? Expert discussion from IMW 2017
Examining strategies to tailor multiple myeloma immunotherapy
Sequencing multiple myeloma using blood tests
